[1] DE SABTIS C,MA J,BRYAN L,et al.Breast cancer statistics 2013[J].CA Cancer J Clin,2014,64(1):52-62.
[2] 孙怡,李俊生.SHIP2在乳腺癌中的表达及其临床意义[J].现代医学,2017,36(12):1761-1764.
[3] 王晨飞,胡浩霖,吕建鑫,等.乳腺癌侵袭相关分子的研究热点[J].东南大学学报(医学版),2018,37(4):734-738.
[4] 刘平贤,门琤,郭满.乳腺癌患者血清VEGF、PRL、HER2、TPS、s CD40L及MVD与复发转移的相关性研究[J].中国妇幼保健,2015,30(9):1377-1379.
[5] 沈恒山,胡健伟,周敏,等.血管内皮生长因子在乳腺癌患者中表达的临床意义[J].中国血液流变学杂志,2016,26(1):17-19.
[6] ZHANG L,WANG H,LI C,et al.VEGF-A/Neuropilin 1 pathway confers cancer stemness via activating wnt/β-catenin axis in breast cancer cells[J].Cell Physiol Biochem,2017,44(3):1251-1262.
[7] 张占东,戚辉,杨超,等.乳腺癌围术期血清血管内皮生长因子-C的变化及其临床意义[J].实用临床医药杂志,2015,19(7):147-148.
[8] LEE S R,ROH Y G,KIM S K,et al.Activation of EZH2 and SUZ12 regulated by E2F1 predicts the disease progression and aggressive characteristics of bladder cancer[J].Clin Cancer Res,2015,21(23):5391-5403.
[9] 汪小霞,孟刚,李丽,等.乳腺癌中EZH2和p53蛋白表达及其临床意义[J].临床与实验病理学杂志,2015,31(11):226-228.
[10] 姚凡,刘崇,房月,等.EZH2在乳腺癌中的表达及其临床意义[J].中国微生态学志,2013,25(2):143-146.
[11] UEDA K,YOSHIMI A,KAGOYA Y,et al.Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p53[J].Cancer Sci,2014,105(5):512-519.
[12] 曹渊,方悦,秦蓉,等.BCL-2与P53的表达对女性乳腺癌新辅助化疗影响的mate分析[J].华西医学,2013,28(11):1671-1674.
[13] CHEN M B,ZHU Y Q,XU J Y.et al.Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer:a meta-analysis[J].PLoS One,2012,7(6):39-55. |